Ipsen: 9m sales up 7.1% (CER)
(CercleFinance.com) - In the first nine months of 2023, the pharmaceutical company Ipsen posted sales of E2.
31bn, up 4.6% as reported and up 7.1% at constant exchange rates (CER).
The group says that this growth at CER was driven by the performance of growth platforms (+16.1%), with Dysport (botulinum toxin type A) and Cabometyx (cabozantinib) up by 24.7% and 24.4% respectively.
Ipsen has confirmed its FY 2023 targete, including total sales growth of over 6% at constant exchange rates, and an operating margin from activities above 30% of total sales.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
31bn, up 4.6% as reported and up 7.1% at constant exchange rates (CER).
The group says that this growth at CER was driven by the performance of growth platforms (+16.1%), with Dysport (botulinum toxin type A) and Cabometyx (cabozantinib) up by 24.7% and 24.4% respectively.
Ipsen has confirmed its FY 2023 targete, including total sales growth of over 6% at constant exchange rates, and an operating margin from activities above 30% of total sales.
Copyright (c) 2023 CercleFinance.com. All rights reserved.